Canaria Bio announced on the 17th that the DSMB (Data Safety Monitoring Board) conducted a futility assessment of the global Phase 3 clinical trial of oregovomab in patients with newly diagnosed ovarian cancer and recommended discontinuation of the clinical trial as the P value required to continue the trial was not achieved.
However, the DSMB suggested that, due to the characteristics of immuno-oncology drugs, there is a possibility of showing meaningful efficacy in overall survival and recommended continued follow-up observation.
Canaria Bio CEO Nahanik said, “We will analyze the causes of the results that differ from those of Phase 2 and establish future plans accordingly.”
Canaria Bio is conducting clinical development through its wholly owned subsidiary Canaria Bio (formerly MHC&C).
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
